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An association between anorexia nerviosa (AN) and low bone mass has been demonstrated. Bone loss associated with AN involves hormonal and
nutritional impairments, though their exact contribution is not clearly established. We compared bone mass in AN patients with women of similar
weight with no criteria for AN, and a third group of healthy, normal-weight, age-matched women. The study included forty-eight patients with AN,
twenty-two healthy eumenorrhoeic women with low weight (LW group; BMI ,18·5 kg/m2) and twenty healthy women with BMI .18·5 kg/m2
(control group), all of similar age. We measured lean body mass, percentage fat mass, total bone mineral content (BMC) and bone mineral density
in lumbar spine (BMD LS) and in total (tBMD). We measured anthropometric parameters, leptin and growth hormone. The control group had
greater tBMD and BMD LS than the other groups, with no differences between the AN and LW groups. No differences were found in tBMD,
BMD LS and total BMC between the restrictive (n 25) and binge–purge type (n 23) in AN patients. In AN, minimum weight (P¼0·002) and
percentage fat mass (P¼0·02) explained BMD LS variation (r 2 0·48) and minimum weight (r 2 0·42; P¼0·002) for tBMD in stepwise regression
analyses. In the LW group, BMI explained BMD LS (r 2 0·72; P¼0·01) and tBMD (r 2 0·57; P¼0·04). We concluded that patients with AN had
similar BMD to healthy thin women. Anthropometric parameters could contribute more significantly than oestrogen deficiency in the achievement
of peak bone mass in AN patients.
Anorexia nervosa: Bone mineral density
Anorexia nervosa (AN) is a common disorder in adolescent girls,
with a prevalence of 0·2–1·0 % in Western societies(1). The
association of AN with low bone mineral density (BMD) has
been conclusively and consistently demonstrated in adult
women(2 – 4) as well as in adolescent girls(5 – 9). Age at diagnosis
and duration of AN determine the severity of bone mineral loss,
whereas factors involved in the location of bone loss are not clear
in AN(10,11). Adolescence represents a critical period for the
achievement of peak bone mass, as most bone mineral is accu-
mulated during the teenage years, and deficits arising during
this time may be permanent. Low peak bone mass is an important
risk factor for osteoporosis and osteoporosis-related fracture
after menopause. Therefore, an understanding of the factors
that impact on bone density during this period is of particular
importance.
Multiple hormone, endocrine and nutritional factors, such as
weight, BMI and degree of undernutrition, affect bone metab-
olism in patients with AN(10,11). To date, the main hormonal
mechanisms known to lead to low bone mass in AN involve
abnormalities in the growth hormone–insulin-like growth
factor I axis. These hormones increase during puberty and
stimulate the proliferation and differentiation of osteoblast
precursors. Insulin-like growth factor I enhances bone for-
mation and growth via effects on osteoblasts and collagen syn-
thesis. Resistance to growth hormone with high growth
hormone levels but low insulin-like growth factor I levels
has been found in patients with AN(6,12 – 14). High cortisol
levels with a normal circadian cycle have been reported.
Hypothalamic dysfunction or corticotropin-releasing hor-
mone overproduction may contribute to hypercorticism(5,13).
Amenorrhoea is a diagnostic criterion for AN, and oestrogen
deficiency has been described as a major source of bone loss
in this condition. The mechanisms underlying this oestrogen
deficiency involve multiple factors including hypothalamic
dysfunction and weight loss(15,16). Over recent years several
other hormonal changes have been observed in AN patients,
such as low levels of testosterone, leptin(7,14), vitamin D(9)
and sex hormone-binding globulin(8). The specific contribution
of these factors to bone remodelling is not completely
understood.
An association between AN and oestrogen deficiency has
been reported, as has a correlation between bone loss and
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the duration of amenorrhoea(6,17). However, most studies failed
to find total bone mass recovery with oestrogen–progestin
therapy(18,19). Oestrogen deficiency does not fully explain
the loss of bone mass associated with AN; malnutrition and
nutrition-dependent factors therefore play a key role in the
pathogenesis of bone loss associated with AN.
We hypothesised that at the beginning of the disease, when
peak bone mass has not yet been reached, factors that involve
bone mineral mass in AN patients are independent, at least in
part, of oestrogen deficit and anthropometric variables and
body composition will better predict bone mineral mass. To
verify this hypothesis, we compared a group of patients with
AN and oestrogen deficit with women of similar low weight
with no criteria for AN (low-weight (LW) group; BMI
,18·5 kg/m2) and therefore with no oestrogen deficit, and a
third group of healthy, normal-weight, age-matched women
(control group; BMI 18·5–25 kg/m2).
Subjects and methods
We studied forty-eight Caucasian adolescent girls who were
referred by general practitioners to our unit for AN (aged 19
(SD 5) years). All of them met the Diagnostic and Statistical
Manual of Mental Disorders 4th edition (DSM-IV) criteria
for AN and secondary amenorrhoea (20 (SD 30) months)
was present at the time of the study. None of them had been
treated with Ca supplements, vitamin D preparations, hormone
therapy, anti-resorptive therapy, thiazides, steroids, or other
medications that might affect bone mass. The LW group
was composed of twenty-two women, aged 18 (SD 4) years,
recruited in primary care centres and who fulfilled the follow-
ing criteria: BMI ,18·5 kg/m2, eumenorrhoeic and no criteria
for eating disorders. Women with co-morbid conditions
known to be associated with secondary bone loss were
excluded. After 5 years of follow-up, none presented any cri-
teria for eating disorders. The control group included twenty
healthy, Caucasian, female adolescents, aged 19·3 (SD 1·5)
years, who were post-menarchal with regular menstrual
periods and no history of eating disorders. Control subjects
with a medical condition or receiving hormone or other medi-
cations known to affect bone metabolism were excluded. All
the participants or their parents gave informed consent and
the study was approved by the Research Committee of
Virgen de la Victoria University Hospital (Malaga, Spain).
Bone mineral density and body composition assessment
BMD at the anterior-posterior lumbar spine L1–L4 (BMD LS)
and total BMD and total bone mineral content were deter-
mined with dual-energy X-ray absorptiometry. The percentage
of total body fat mass and lean body mass was quantified
using the dual-energy X-ray absorptiometry method (Lunar
DPX-L; Lunar Corp., Madison, WI, USA).
Biochemical measurements
Morning fasting samples of venous blood were taken. Serum
was promptly separated and stored at 2808C until assay.
Serum growth hormone (Immunotech IRMA kit Beckman
Coulter; manufacturer’s reference level ,5 mU/l) was
assayed. Serum leptin (RIA; Nichols Institute Diagnostics,
Heston, Middlesex, UK; manufacturer’s reference range for
a normal BMI (18·5–25 kg/m2): 3·7–11·1mg/l; analytical sen-
sitivity: 0·5 ng/ml) was also measured.
Statistical analysis
For the descriptive analysis all values are presented as mean
values and standard deviations. The comparison between
quantitative variables was done with the ANOVA test. Inter-
group comparisons were performed using the Student t test
and Mann–Whitney test in parametric and non-parametric
comparisons, respectively. For the bivariate analysis we used
simple linear (bivariate) correlations in all study groups to
evaluate several interactions: anthropometric, nutritional and
hormone parameters. Statistical significance was set at
P,0·05. A multivariate analysis was carried out to evaluate
the impact of anthropometric and hormone parameters on
BMD LS and total BMD in the AN patients and the LW
group as well as a multivariate linear regression (stepwise
addition). Inclusion of hormone, clinical and anthropometric
variables in the analysis was based on the strength of corre-
lation with BMD. All statistical analyses were performed
with SPSS 13.0 (SPSS, Inc., Chicago, IL, USA).
Results
Table 1 shows the clinical characteristics of the study popu-
lation. The control group had a higher total BMD and BMD
LS than the AN and LW groups after adjusting for age,
height and weight. No significant differences were found
between the AN and LW groups in age, weight, height or
BMI. Leptin levels and the percentage of fat mass were sig-
nificantly lower (both P,0·001) in the AN group compared
with the LW group, regardless of age. No significant differ-
ences were found in bone mass parameters between the two
groups for total bone mineral content, total BMD or BMD
LS. Regarding the two types of AN patients, the anthropo-
metric parameters were similar in all the patients, regardless
of whether they had the restrictive or the binge–purge variant
of AN. No significant differences were found in total bone
mineral content, total BMD or BMD LS, or in the other par-
ameters, including leptin and growth hormone (Table 2).
Bivariate analysis in the AN group showed positive corre-
lations between bone parameters and anthropometric par-
ameters such as minimum weight, weight and BMI (Table 3).
No correlations were found between bone markers, age and
duration of AN and amenorrhoea. In the LW group, anthropo-
metric parameters such as weight and BMI were correlated
with total bone mineral content and total BMD. No correlation
was found between BMD LS and anthropometric parameters
(Table 3).
In the multivariate analysis (Table 4), an important influ-
ence of the anthropometric parameters in BMD was shown
in the AN group. Minimum weight during the illness and
percentage fat mass accounted for 48 % of the BMD LS vari-
ance, while 42 % of the total BMD variance was determined
by minimum weight during the illness. In the LW group, up
to 72 % of the variance in BMD LS was due to BMI, and
57 % of the total BMD variance was explained by the BMI.


















Previous studies have shown that osteopenia occurs in 50 % of
young women with AN at both trabecular and cortical bone
sites. Fractures are common in these young osteoporotic
patients(2 – 8). These abnormalities result from the uncoupling
of bone remodelling, including decreased bone formation
and increased bone resorption(20). Factors responsible for
low bone mass in AN patients involve interrelated multiple
hormone and nutritional impairments that damage osteoblast
and/or osteoclast activities. This model differs from the post-
menopausal osteoporosis model, where oestrogen deficiency
only determines an increase in bone resorption. Several hor-
mone mechanisms are currently known to lead to low bone
mass. The specific contribution of these factors on bone remo-
delling, though, is not completely understood(5 – 9,13 – 16).
In the present study, we compared three different groups of
teenagers and young adult women, all of similar age: a group
of healthy, normal-weight women, a group of eumenorrhoeic
women with BMI ,18·5 kg/m2 with no criteria for AN
(LW group) and a group of AN patients having a mean of
18 months’ disease evolution and of similar weight to the
LW group. The study of these three different groups enabled
us to evaluate the independent contribution of oestrogen defi-
cit and weight to bone mineral mass at the onset of the disease.
The association between the hypo-oestrogenic state and early
onset bone loss in AN patients(21) and the need to reach
normal oestrogen levels during this period of bone mass acqui-
sition(22) have been reported previously. Klibanski et al.
showed in a prospective study that oestrogen administration
was effective in preventing progressive osteopenia in lean
AN patients only when associated with weight gain(16). The
reason why oestrogen replacement alone is not sufficient to
promote bone accretion in young patients with AN is currently
unknown, but it may well mean that proper nutrition and
recovery of normal circulating bone trophic factors such as
insulin-like growth factor I are required for oestrogen action
on bone.
Table 1. Clinical characteristics of the study population
(Mean values and standard deviations)
Control group AN group LW group
Characteristic Mean SD Mean SD Mean SD
Age (years) 19·30 1·55 19·00 5·1 19·65 5·34
Height (cm) 160·72 5·83 159·90 6·69 159·92 5·29
Weight (kg) 54·4 5·39 44·28* 5·0 43·44* 5·29
BMI (kg/m2) 22·30 1·59 16·13* 1·53 16·65* 1·02
Age at onset of illness (years) – 16·51 3·31 –
Duration of amenorrhoea (months) – 20·45 31·4 –
Total fat mass (%) – 15·37 5·63 20·63† 3·40
Lean body mass (g) – 35 404·26 3706·23 34 358·10 3915·21
Total bone mineral content (g) – 2010·86 383·73 1939·60 327·10
Bone mineral density in the lumbar spine (g/cm2) 1·049 0·06 0·958* 0·13 0·956* 0·13
Total bone mineral density (g/cm2) 1·115 0·08 1·075* 0·11 1·067* 0·09
Leptin (ng/ml) 8·96 1·91 1·90* 1·76 4·36*† 2·01
Growth hormone (ng/ml) – 3·67 2·93 3·07 5
AN, anorexia nervosa; LW, low weight.
* Mean value was significantly different from that of the control group (P,0·001).
† Mean value was significantly different from that of the AN group (P,0·001).
Table 2. Differences between restrictive and purgative types within the anorexia nervosa group
(Mean values and standard deviations)
Purgative (n 23) Restrictive (n 25)
Mean SD Mean SD Significance
Minimum weight (kg) 39·18 3·72 38·5 5·59 NS
Age at onset of illness (years) 16·85 2·47 16·32 3·8 NS
Duration of amenorrhoea (months) 29·4 44·91 16·00 19·16 NS
Weight (kg) 41·52 4·98 41·13 5·28 NS
Height (m) 1·60 0·06 1·59 0·069 NS
BMI (kg/m2) 16·15 1·59 16·12 1·53 NS
Leptin (ng/ml) 2·8 2·32 1·33 1·01 NS
Growth hormone (ng/ml) 4·91 3·67 3·3 2·64 NS
Bone mineral density in the lumbar spine (g/cm2) 0·948 0·111 0·964 0·121 NS
Total bone mineral density (g/cm2) 1·073 0·099 1·076 0·105 NS
Total bone mineral content (g) 2012·27 258·79 2009·45 353·17 NS
Lean body mass (g) 34 877·44 2778·73 35 787·41 4280·33 NS
Total fat mass (%) 16·60 6·15 14·47 5·18 NS

















The first outstanding result in the present study was that the
LW women had the same bone mineral mass as the AN
patients. Both groups had lower total BMD and BMD LS
than healthy women of a similar age. In the present study,
BMD LS and total BMD in AN and LW patients were signifi-
cantly related to anthropometric variables, though the duration
of amenorrhoea did not explain the changes in BMD in the
AN patients. Consequently, these results suggest that anthro-
pometric parameters could contribute more significantly than
oestrogen deficit in the AN patients of short evolution. A simi-
lar decrease in BMD in the LW group and the AN patients
strengthens this theory. The relationship between BMI and
BMD in AN patients and healthy women has been reported
previously. Several studies have demonstrated that body
weight in healthy premenopausal women is an independent
and determinant factor for adequate peak bone mass in this
population(23 – 25). Bone loss is inversely correlated with
weight in AN patients. Greater weight loss(26,27) and a
longer duration of the low weight state(28) produce a higher
bone loss. Similarly, there was a correlation with lean mass,
which is supported by previous studies where the loss of
lean mass was considered an important prognostic factor to
predict the bone mass loss, with a significant correlation
between lean mass and BMD LS and total BMD(29,30).
The present study revealed no differences between the two
forms of AN, the restrictive and the binge–purge types, either
in bone or anthropometric parameters. Previous studies com-
paring the bone density between the two different forms of
AN have yielded inconsistent findings(31 – 34). The present
results are consistent with data suggesting that the degree of
underweight is an important predictor of low BMD, whereas
other behaviour such as bingeing and purging seems to be
of relatively minor importance. Discrimination between the
two AN types is based on behavioural symptoms (for example,
purging) that frequently change during the course of the
illness(35,36). This heterogeneity is associated with a masking
of the differences in effects that restrictive and binge–purge
eating behaviours might have on bone parameters.
Leptin exerts a critical role in the regulation of body energy
balance and as a protective factor inhibiting bone resorp-
tion(37 – 39). However, the exact mechanism underlying the
effect of variation in this adipokine on bone anomalies in
patients with AN is still not clear. The decrease in leptin
levels observed in AN patients could contribute to BMD
loss due to the reduction in bone formation(10). Additionally,
the correlation between leptin and bone resorption markers
in AN patients during the refeeding process suggests a poss-
ible cause–effect relationship between serum levels of leptin
and bone metabolism(40). Conversely, leptin deficiency in
AN was not an independent predictor of BMD after control-
ling for other nutrition-dependent factors such as BMI.
Despite the marked decrease in serum leptin levels in the
AN group compared with the LW group no changes in
BMD were revealed.
The present study has several limitations. First, hypo-
oestrogenism was defined by a surrogate value, duration of ame-
norrhoea, because oestradiol or gonadotrophin serum levels
were unavailable. Second, in our study, comparison groups
were small. However, there are not many papers reporting
differences between patients with AN, healthy women with
LW and women with normal weight. Third, BMD could not be
adjusted for 25-hydroxyvitamin D levels, an important cause
in the pathophysiology of bone alterations in AN.
Table 3. Correlation analysis of the biological variables studied (Pearson’s r) in the anorexia nervosa
(AN) and low-weight (LW) groups
BMD LS Total BMD Total BMC
AN LW AN LW AN LW
Age 0·01 0·27 0·06 0·28 0·13 0·41
Illness duration 20·08 – 20·14 – 20·12 –
Minimum weight 0·60** – 0·69** – 0·83** –
Weight 0·46* 0·47 0·59** 0·32* 0·76** 0·84**
BMI 0·51** 0·53 0·49** 0·54* 0·45** 0·73**
Months of amenorrhoea 20·06 – 20·11 – 20·21 –
Percentage total fat mass 0·24 0·35 0·14 0·22 0·16 0·27
Lean body mass 0·36 0·32 0·54** 0·22 0·76** 0·84**
Leptin 0·02 20·01 0·01 0·02 0·06 20·23
Growth hormone 0·13 0·26* 0·19 0·29* 0·16 0·69**
BMD LS, bone mineral density in the lumbar spine; BMD, bone mineral density; BMC, bone mineral content.
*P,0·05, **P,0·001.










Minimum weight 0·48 0·46 0·002
% Fat mass 0·44 0·02
BMI 0·72 0·85 0·01
Total BMD
Independent variables
Minimum weight 0·42 0·65 0·002
BMI 0·57 0·72 0·04
BMD LS, bone mineral density in the lumbar spine; BMD, bone mineral density.
* Dependent variables: BMD LS and total BMD. Independent variables: age, mini-
mum weight, lean body mass, percentage fat mass, time of disease evolution,
months of amenorrhoea, BMI, leptin and growth hormone (minimum weight, time
of disease evolution, months of amenorrhoea not included in the LW model).
Statistical significance set at P,0·05.

















In conclusion, the present results support the hypothesis that
anthropometric parameters could contribute more significantly
to low bone mass than oestrogen deficiency in AN patients of
short evolution. Therefore, teenagers and adult women with
low weight have an increased risk for low bone mass similar
to that of AN patients.
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